Lilly – Ajax JAK2 Deal ($2.3B)

Summary Eli Lilly has entered a definitive agreement to acquire Ajax Therapeutics in a deal worth up to $2.3 billion to secure AJ1-11095, a first-in-class Type II JAK2 inhibitor for myelofibrosis and polycythemia vera, positioning Lilly in the next-generation JAK inhibitor landscape. What Happened Lilly…